HD-OPM Archive
Topics › PCSK9, ezetimibe & newer drugs

PCSK9 inhibition may slow cardiometabolic aging beyond lowering cholesterol

Louis Nervegna · Dec 21, 2023 · ♥ 15 reactions · 11 comments · original Facebook post
PCSK9, ezetimibe & newer drugsAging & longevityLDL, ApoB & lipid panel
AI summary & key facts

Louis highlights a GeroScience open-access review proposing PCSK9 inhibition may ameliorate age-related cardiac and liver pathology, and that a multivariate genome-wide analysis of aging traits identified PCSK9 as a potential drug target for healthy aging. He adds that botanical compounds such as berberine also inhibit PCSK9. The anti-aging role remains an emerging research area.

Inhibition of PCSK9 doesn’t just lower cholesterol. It may also slow aging of the cardiovascular system, and other organ systems like the liver. This is an exciting new research area that connects cardiology with the science of aging.

Note that it’s not just drugs that inhibit PCSK9. Many botanical compounds do as well (e.g. berberine). See comments for a list.

——

Quoted:

“In conclusion, PCSK9’s association with cardiovascular aging is a rapidly evolving area of research with significant implications for our understanding of age-related cardiovascular disease. Studies measuring plasma PCSK9 levels, along with investigations into the links between liver health, lipid metabolism, and cardiac function, have begun to uncover the intricate relationships between PCSK9 and cardiovascular aging. The cumulative evidence from various studies suggests that PCSK9 inhibition offers a promising avenue for ameliorating age-related cardiac and hepatic pathologies by targeting both systemic and local factors. Importantly, a recent multivariate genome-wide analysis of aging-related traits identified PCSK9 as a potential new drug target for healthy aging [26]. As the understanding of PCSK9’s multifaceted role in aging and age-related diseases continues to evolve, exploring the therapeutic potential of PCSK9 inhibition in the context of cardiometabolic aging remains an exciting and dynamic area of research.”

#pcsk9HD #agingHD #longevityHD #liverHD

Research cited

Shared from GeroScience · original post

📢New Open🔓 Access Review

PCSK9: an emerging player in cardiometabolic aging and its potential as a therapeutic target and biomarker by Anna Csiszar, Stefano Tarantini, Andriy Yabluchanskiy & Zoltan Ungvari.

Paper · GeroScience · 2023PCSK9: an emerging player in cardiometabolic aging and its potential as a therapeutic target and biomarkerProprotein convertase subtilisin/kexin type 9 (PCSK9), renowned for its pivotal role in low-density lipoprotein (LDL) regulation, has emerged as a compelling regulator of cardiometabolic aging. Beyond its well-established involvement in cholesterol metabolism, PCSK9’s multifaceted influence on the aging processes of the cardiovascular and metabolic systems is garnering increasing attention. This review delves into…link.springer.com

#aging #inflammaging #cardiovasculardisease #hepaticaging #lipidmetabolism #cardiovascularhealth

No photo description available.
← newer: Low LDL's link to cancer is reverse causality: cancer lowersolder: Louis: heart-disease death rates have been falling for decad →